Abstract
Background Though several SAPAP3 gene knockout studies in mice have implicated its role in compulsivity, human studies have failed to demonstrate its association with obsessive-compulsive disorder (OCD). We examined the association between allelic variants of a single nucleotide polymorphism in the SAPAP3 gene (rs6662980) with specific aspects of the OCD phenotype.
Methods A total of 200 subjects with OCD were genotyped using the TaqMan assay. All subjects were assessed using Mini International Neuropsychiatric Interview, the Yale-Brown Obsessive-Compulsive Scale, and their treatment response was evaluated over naturalistic treatment and follow-up.
Results After correcting for multiple comparisons, G-allele at rs6662980 was found to be associated with contamination/washing symptoms (p=0.003). Logistic regression analysis also showed that presence of G allele predicted poor response to serotonin reuptake inhibitors [odds ratio = 2.473 (95% CI = 1.157 - 5.407), p=0.021]. Interaction between presence of G-allele and contamination factor score predicted SRI resistance (B= 1.197, p = 0.006).
Limitations We did not use a dimensional measure for assessing OCD symptoms. Treatment response was assessed over naturalistic follow-up.
Conclusion Specific phenotypic manifestations of OCD, which include contamination and washing-related symptoms along with resistance to serotonin reuptake inhibitors, may be related to alterations in the SAPAP3 gene.
Public Significance Statement “This study finds that a specific polymorphism in the SAPAP3 gene, was found to be associated with the contamination/washing symptoms of OCD and was also found to predict resistance to pharmacological treatment”
Highlights
SAPAP3 gene is implicated in OCD
Association of SAPAP3 gene (rs6662980) with OCD phenotypes was examined
Presence of the minor (G) allele predicted contamination & washing symptoms
SAPAP3 polymorphism had a significant association with treatment response
Interaction between presence of G-allele and contamination factor score predicted treatment resistance
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has been supported by various research grants from Department of Biotechnology, Department of Science & Technology and the Indian Council Medical Research, Ministry of Health & Family Welfare, Government of India. SN, SB and RS are funded by the Accelerator program for Discovery in Brain disorders in Stem cells, a joint venture of the Department of Biotechnology. Government of India and the Pratiksha trust.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data associated with findings presented in the manuscript are included in Tables. Any additional data that readers/reviewers may need, may be requested from the corresponding author.
